LOWELL, Mass., July 21, 2016 /PRNewswire/ -- InfoBionic, Inc. today announced that BioTelemetry, Inc. and InfoBionic agreed to dispose of BioTelemetry's obsolete claims of patent infringement against a first-generation device. InfoBionic is pleased to offer its state-of-the-art, FDA-cleared second-generation MoMe® Kardia System to physicians.
After a study showed patients did not like using a two-piece device, InfoBionic decided in August last year not to commercialize its first-generation MoMe® Kardia device. InfoBionic and BioTelemetry entered into a judgment in the District of Massachusetts resolving BioTelemetry's patent claims against this first-generation device. As part of this agreement no damages were incurred by InfoBionic and no monies were due.
InfoBionic's second-generation MoMe® Kardia device, a single 3-in-1 device which streams full disclosure cardiac arrhythmia detection and monitoring data using cellular technology, is already commercially available. Harnessing the power of the Cloud to deliver actionable, on-demand results directly to physicians, it transforms the efficiency and economics of cardiac arrhythmia detection and monitoring with an innovative Software as a Service (SaaS) model. BioTelemetry agreed that InfoBionic's second-generation MoMe® Kardia system is unaffected by the judgment.
InfoBionic is pleased to have dispensed with part of the pending litigation and will vigorously defend its transformative MoMe® Kardia platform against BioTelemetry's remaining claims. At this time, the U.S. Patent Office already has found that InfoBionic demonstrated a reasonable likelihood that it will prevail in having claims of two BioTelemetry patents declared invalid, and a motion to invalidate the remaining asserted patents is pending in court.
InfoBionic is an emerging digital health company focused on creating superior patient monitoring solutions for chronic disease management with an initial market focus on cardiac arrhythmias. For more information please visit www.infobionic.com.